Biomedical Research Centre

In 2016 Manchester was awarded a National Institute of Health Research (NIHR) Biomedical Research Centre (BRC). The NIHR BRC designation is awarded only to NHS/University partnerships that can demonstrate the highest levels of both existing research excellence internationally across a substantial portfolio and an existing portfolio of research facilities. The successful bid is hosted by Manchester University NHS Foundation Trust, in partnership with The University of Manchester. The partnership also encompasses The Christie NHS Foundation Trust, Salford Royal NHS Foundation Trust, University Hospital of South Manchester NHS Foundation Trust and is supported by Manchester Academic Health Science Centre.

The aims of the NIHR BRCs are to:

  • drive innovation in the prevention, diagnosis and treatment of ill-health through people and/or patient-focussed early translational (experimental medicine) research;
  • translate advances in biomedical research into benefits for patients, the health system and for broader economic gain
  • provide a key component of the NHS contribution to our nation’s international competitiveness.

NIHR BRCs are designated on a 5 year basis, with the BRC funding designation starting on 1st April 2017 until 31st March 2022.

  • In this 5 year funding package a total of £816 million across 20 BRCs awarded – the largest ever investment into health research.
  • Manchester has expanded from a single theme, £5.5 million Biomedical Research Unit into a comprehensive £28.5 million BRC.

The Manchester NIHR BRC consists of 7 themes. This will drive forward pioneering research into new tests and treatments in the areas of musculoskeletal disease, hearing health, respiratory disease and dermatology and three cancer themes (prevention and early detection (PED), radiotherapy and precision medicine). MCGM is a key participant in several of these themes:

Please visit the Manchester BRC website for further information.